Thrombopoietin receptor agonists in hereditary thrombocytopenias

F. Rodeghiero, A. Pecci, C. L. Balduini

Research output: Contribution to journalArticle

Abstract

Hereditary thrombocytopenias (HTPs) constitute a heterogeneous group of diseases characterized by a reduction in platelet count and a potential bleeding risk. As a result of advances in diagnostic methods, HTPs are increasingly being identified, and appear to be less rare than previously thought. Most HTPs do not have effective treatments, except for platelet transfusion when bleeding occurs and in preparation for procedures associated with a risk of bleeding. Preliminary clinical evidence suggests that thrombopoietin receptor agonists (TPO-RAs) with an established use in the treatment of certain acquired thrombocytopenias are well tolerated and provide clinical benefits in patients with some forms of HTP. These drugs may therefore be considered for the treatment of HTPs in clinical practice. However, caution and close monitoring are recommended, owing to the absence of long-term safety data and the potential risks posed by prolonged bone marrow stimulation in certain HTPs. In this review, we summarize the available clinical data on TPO-RAs in the treatment of HTPs, and discuss their use in patients with these disorders. We believe that TPO-RAs will play a major role in the treatment of HTPs, particularly myosin heavy chain 9-related disease, Wiskott-Aldrich syndrome, X-linked thrombocytopenia, and thrombocytopenia caused by THPO mutations.

Original languageEnglish
JournalJournal of Thrombosis and Haemostasis
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Thrombopoietin Receptors
Hemorrhage
Wiskott-Aldrich Syndrome
Therapeutics
Platelet Transfusion
Myosin Heavy Chains
Platelet Count
Thrombocytopenia
Bone Marrow
Safety
Mutation
Pharmaceutical Preparations

Keywords

  • Bernard-Soulier syndrome
  • Eltrombopag
  • MYH9-related disease
  • Romiplostim
  • Thrombocytopenia

ASJC Scopus subject areas

  • Hematology

Cite this

Thrombopoietin receptor agonists in hereditary thrombocytopenias. / Rodeghiero, F.; Pecci, A.; Balduini, C. L.

In: Journal of Thrombosis and Haemostasis, 01.01.2018.

Research output: Contribution to journalArticle

@article{f00c36371ee64c599e0d32b8c982fdf8,
title = "Thrombopoietin receptor agonists in hereditary thrombocytopenias",
abstract = "Hereditary thrombocytopenias (HTPs) constitute a heterogeneous group of diseases characterized by a reduction in platelet count and a potential bleeding risk. As a result of advances in diagnostic methods, HTPs are increasingly being identified, and appear to be less rare than previously thought. Most HTPs do not have effective treatments, except for platelet transfusion when bleeding occurs and in preparation for procedures associated with a risk of bleeding. Preliminary clinical evidence suggests that thrombopoietin receptor agonists (TPO-RAs) with an established use in the treatment of certain acquired thrombocytopenias are well tolerated and provide clinical benefits in patients with some forms of HTP. These drugs may therefore be considered for the treatment of HTPs in clinical practice. However, caution and close monitoring are recommended, owing to the absence of long-term safety data and the potential risks posed by prolonged bone marrow stimulation in certain HTPs. In this review, we summarize the available clinical data on TPO-RAs in the treatment of HTPs, and discuss their use in patients with these disorders. We believe that TPO-RAs will play a major role in the treatment of HTPs, particularly myosin heavy chain 9-related disease, Wiskott-Aldrich syndrome, X-linked thrombocytopenia, and thrombocytopenia caused by THPO mutations.",
keywords = "Bernard-Soulier syndrome, Eltrombopag, MYH9-related disease, Romiplostim, Thrombocytopenia",
author = "F. Rodeghiero and A. Pecci and Balduini, {C. L.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/jth.14217",
language = "English",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Thrombopoietin receptor agonists in hereditary thrombocytopenias

AU - Rodeghiero, F.

AU - Pecci, A.

AU - Balduini, C. L.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Hereditary thrombocytopenias (HTPs) constitute a heterogeneous group of diseases characterized by a reduction in platelet count and a potential bleeding risk. As a result of advances in diagnostic methods, HTPs are increasingly being identified, and appear to be less rare than previously thought. Most HTPs do not have effective treatments, except for platelet transfusion when bleeding occurs and in preparation for procedures associated with a risk of bleeding. Preliminary clinical evidence suggests that thrombopoietin receptor agonists (TPO-RAs) with an established use in the treatment of certain acquired thrombocytopenias are well tolerated and provide clinical benefits in patients with some forms of HTP. These drugs may therefore be considered for the treatment of HTPs in clinical practice. However, caution and close monitoring are recommended, owing to the absence of long-term safety data and the potential risks posed by prolonged bone marrow stimulation in certain HTPs. In this review, we summarize the available clinical data on TPO-RAs in the treatment of HTPs, and discuss their use in patients with these disorders. We believe that TPO-RAs will play a major role in the treatment of HTPs, particularly myosin heavy chain 9-related disease, Wiskott-Aldrich syndrome, X-linked thrombocytopenia, and thrombocytopenia caused by THPO mutations.

AB - Hereditary thrombocytopenias (HTPs) constitute a heterogeneous group of diseases characterized by a reduction in platelet count and a potential bleeding risk. As a result of advances in diagnostic methods, HTPs are increasingly being identified, and appear to be less rare than previously thought. Most HTPs do not have effective treatments, except for platelet transfusion when bleeding occurs and in preparation for procedures associated with a risk of bleeding. Preliminary clinical evidence suggests that thrombopoietin receptor agonists (TPO-RAs) with an established use in the treatment of certain acquired thrombocytopenias are well tolerated and provide clinical benefits in patients with some forms of HTP. These drugs may therefore be considered for the treatment of HTPs in clinical practice. However, caution and close monitoring are recommended, owing to the absence of long-term safety data and the potential risks posed by prolonged bone marrow stimulation in certain HTPs. In this review, we summarize the available clinical data on TPO-RAs in the treatment of HTPs, and discuss their use in patients with these disorders. We believe that TPO-RAs will play a major role in the treatment of HTPs, particularly myosin heavy chain 9-related disease, Wiskott-Aldrich syndrome, X-linked thrombocytopenia, and thrombocytopenia caused by THPO mutations.

KW - Bernard-Soulier syndrome

KW - Eltrombopag

KW - MYH9-related disease

KW - Romiplostim

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=85051101651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051101651&partnerID=8YFLogxK

U2 - 10.1111/jth.14217

DO - 10.1111/jth.14217

M3 - Article

AN - SCOPUS:85051101651

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

ER -